MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)

PHASE3CompletedINTERVENTIONAL
Enrollment

530

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

sitagliptin phosphate

Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks.

DRUG

Comparator: placebo

placebo to match Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00289848 - MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040) | Biotech Hunter | Biotech Hunter